Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan

被引：0
|
作者：
Mai, Nicholas
Klar, Miriam
Ferraro, Emanuela
Bromberg, Maria
Chen, Yuan
Razavi, Pedram
Modi, Shanu
Chandarlapaty, Sarat
Walsh, Elaine M.
Drago, Joshua Z.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA
[3] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1085
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
    Testa, Stefano
    Dickerson, James C.
    Telli, Melinda
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 11
  • [2] Real-world outcomes of sacituzumab govitecan in breast cancer
    Singh, Vaishnavi
    Dhaibar, Hemangini
    Peddi, Prakash
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patientsda multicenter real-world analysis
    Dannehl, D.
    Jakob, D.
    Mergel, F.
    Estler, A.
    Engler, T.
    Volmer, L.
    Frevert, M-L
    Matovina, S.
    Englisch, A.
    Tegeler, C. M.
    Rohner, A.
    Seller, A.
    Hahn, M.
    Pfister, K.
    Fink, A.
    Popp, I.
    Lorenz, S.
    Tabatabai, G.
    Juhasz-Boess, I.
    Janni, W.
    Brucker, S.
    Taran, F. -A
    Hartkopf, A.
    Schaeffler, H.
    ESMO OPEN, 2024, 9 (05)
  • [4] Real-world activity of sacituzumab govitecan for metastatic breast cancer
    Morganti, S.
    Kusmick, R.
    Hughes, M. E.
    Braso-Maristany, F.
    Smith, K.
    Tarantino, P.
    Vega Leon, M. D. R.
    Grinda, T.
    Pardo, F.
    Dvir, K.
    Suggs, G.
    Buck, S.
    Skeffington, M.
    Garrido-Castro, A. C.
    Parsons, H.
    Sammons, S.
    Prat, A.
    Lin, N.
    Tolaney, S. M.
    Giordano, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S382 - S382
  • [5] Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
    Poumeaud, F.
    Morisseau, M.
    Cabel, L.
    Goncalves, A.
    Rivier, C.
    Tredan, O.
    Volant, E.
    Frenel, J. -s.
    Ladoire, S.
    Jacot, W.
    Jamelot, M.
    Foka Tichoue, H.
    Patsouris, A.
    Teixeira, L.
    Bidard, F. -c.
    Loirat, D.
    Brunet, M.
    Levy, C.
    Bailleux, C.
    Cabarrou, B.
    Deleuze, A.
    Uwer, L.
    Deluche, E.
    Grellety, T.
    Franchet, C.
    Fiteni, F.
    Bischoff, H.
    Vion, R.
    Pagliuca, M.
    Verret, B.
    Becourt, S.
    Reverdy, T.
    de Nonneville, A.
    Dalenc, F.
    BRITISH JOURNAL OF CANCER, 2024, 131 (04) : 702 - 708
  • [6] Sacituzumab Govitecan Toxicity Outcomes In Arab Patients with Metastatic Breast Cancer
    Altarturi, Maymouna
    Suleman, Kausar
    AlSayed, Adhar
    Al-Shamsi, Humaid
    Alawadhi, Aydah
    Basuliamn, Bassam
    Alaklabi, Sabah
    CANCER RESEARCH, 2024, 84 (09)
  • [7] Real-world data on the safety and efficacy of trastuzumab deruxtecan and sacituzumab govitecan in patients with advanced breast cancer: the experience of the Hellenic Cooperative Oncology Group
    Fountzilas, E.
    Lalla, T.
    Karakatsoulis, G.
    Papazisis, K.
    Exarchos, K.
    Koumarianou, A.
    Nikolaidi, A.
    Binas, I.
    Mauri, D.
    Karageorgopoulou, S.
    Razis, E.
    Christopoulou, A.
    Boutis, A.
    Douganiotis, G.
    Zagouri, F.
    Stamatopoulou, S.
    Spathas, N.
    Tryfonopoulos, D.
    Psyrri, A.
    Koutras, A.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 2 - 2
  • [8] Real World Outcomes with Sacituzumab Govitecan in Metastatic Triple Negative Breast Cancer Patients: A Multi-Institution Study
    Alaklabi, Sabah
    Roy, Arya Mariam
    Zagami, Paola
    Held, Nicole
    Shaikh, Saba
    Chaudhary, Lubna
    Abdou, Yara
    Gandhi, Shipra
    CANCER RESEARCH, 2024, 84 (09)
  • [9] Sacituzumab govitecan in metastatic Breast Cancer Optimal Interaction: ADC-based Therapy and Radiotherapy
    Schoellmann, Claudia
    BREAST CARE, 2024, 19 (04) : 236 - 238
  • [10] Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan
    McGuinness, Julia E.
    Kalinsky, Kevin
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 903 - 913
12345